Pembrolizumab

(Keytruda®)

Pembrolizumab

Drug updated on 6/25/2024

Dosage FormInjection (intravenous: 100 mg/4 mL [25 mg/mL])
Drug ClassProgrammed death receptor-1 (PD-1) blocking antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of patients with unresectable or metastatic melanoma.
  • Indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.
  • Indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
  • Indicated in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
  • Indicated as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: -Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or -metastatic.
  • Indicated as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
  • Indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
  • Indicated as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
  • Indicated in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell cancer (HNSCC).
  • Indicated as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.
  • Indicated as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
  • Indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
  • Indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
  • Indicated for the treatment of adult and pediatric patients with refractory primary eediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
  • Indicated in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
  • Indicated as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
  • Indicated as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
  • Indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options
  • Indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.
  • Indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
  • Indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • Indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either in combination with platinum- and fluoropyrimidine-based chemotherapy, or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
  • Indicated in combination with chemoradiotherapy, for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.
  • Indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
  • Indicated as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
  • Indicated for the treatment of patients with Hepatocellular Carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD1/PD-L1-containing regimen.
  • Indicated in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
  • Indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
  • Indicated in combination with axitinib, for the first-line treatment of adult patients with advanced Renal Cell Carcinoma (RCC).
  • Indicated in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.
  • Indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
  • Indicated in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
  • Indicated in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDAapproved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
  • Indicated as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
  • Indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
  • Indicated for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation.
  • Indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
  • Indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Pembrolizumab (Keytruda) is indicated for the treatment of various conditions including unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), and others. It can be used as a single agent or in combination with other therapies.
  • A total of 105 studies were reviewed to gather information about pembrolizumab's safety and effectiveness across different indications.
  • Compared to chemotherapy alone, immune checkpoint inhibitors like pembrolizumab generally improved overall survival and progression-free survival in patients with advanced NSCLC. PD-L1 expression greater than or equal to 1% was found to be a significant predictor of improved outcomes.
  • When combined with chemotherapy, pembrolizumab showed superior efficacy compared to its use as monotherapy for advanced NSCLC patients who have a PD-L1 Tumor Proportion Score greater than or equal to 50%.
  • For metastatic melanoma treatment, pembrolizumab, along with other immune checkpoint inhibitors, demonstrated significant survival benefits. However, combining nivolumab and ipilimumab could potentially offer better overall survival but may lead to higher incidences of treatment-related adverse events.
  • The risk profile associated with using pembrolizumab varied across studies; it appeared that factors such as the level of PD-L1 expression, histological subtype, e.g., nonsquamous vs squamous NSCLC, influenced this risk profile significantly.
  • Pembrolizumab has been identified as an effective first-line therapy when combined with chemotherapy for treating advanced NSLC, irrespective of their levels on PD-L1 expressions, especially those suffering from non-squamous carcinomas.
  • In cases where metastatic melanoma was diagnosed, different immune checkpoint inhibitors displayed varying degrees of efficacies and safety profiles. Pembrolizumab was generally well-tolerated and effective, especially in patients with higher PD-L1 expression.
  • The combination of pembrolizumab with other agents has demonstrated significant efficacy across various cancer types, particularly in specific patient subgroups defined by PD-L1 expression and histological subtype. This represents a shift towards more personalized and effective cancer therapies.
  • The comparative risk of treatment-related adverse events (TRAEs), particularly with combination therapies, necessitates careful patient selection and monitoring. Further research into optimal combination strategies remains critical to enhancing outcomes while managing adverse effects effectively.

Product Monograph / Prescribing Information

Document TitleYearSource
Keytruda (pembrolizumab) Prescribing Information.2024Merck & Co., Whitehouse Station, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparison of immune checkpoint inhibitors related to pulmonary adverse events: A retrospective analysis of clinical studies and network meta-analysis. 2024BMC Medicine
Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.2023International Immunopharmacology
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.2023EBioMedicine
The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis.2023Clinical Genitourinary Cancer
Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis.2023Lung Cancer
Anti-TIGIT therapies for solid tumors: A systematic review.2023ESMO
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.2023Lung Cancer
Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis2023Human Vaccines & Immunotherapeutics
Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: A systematic review and meta-analysis of 20 prospective studies2023Hematology
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.2023International Journal of Urology
Effectiveness and safety of pembrolizumab in recurrent and relapsed classic Hodgkin Lymphoma: A systematic review. 2023Cureus
Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: A systematic review and network meta-analysis. 2023Frontiers in Pharmacology
A network meta-analysis evaluating the efficacy and safety of adjuvant therapy after nephrectomy in renal cell carcinoma.2023BioMed Central Urology
Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50.2023BioMed Central Cancer
Immune checkpoint inhibitors serve as the first-line treatment for advanced head and neck cancer.2023The Laryngoscope
Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: A systematic review and network meta-analysis. 2023Frontiers in Endocrinology
Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: A systematic review and network meta-analysis.2023Frontiers in Pharmacology
Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: A systematic review and Bayesian network meta-analysis. 2023Therapeutic Advances in Chronic Disease
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: A systematic review and network meta-analysis. 2023BioMed Central Cancer
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.2023PLoS One
Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis.2023Human Vaccines & Immunotherapeutics
Pembrolizumab plus lenvatinib in advanced endometrial cancer: Case report and systematic review of lung toxicity.2023Frontiers in Oncology
Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: A systematic review and meta-analysis of 20 prospective studies.2023Hematology
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.2023International Journal of Urology
First-line therapy for adults with advanced renal cell carcinoma: A systematic review and network meta-analysis. 2023The Cochrane Database of Systematic Reviews
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: The MOUSEION-03 meta-analysis. 2023Cancer Immunology and Immunotherapy
Combined or sequential treatment with immune checkpoint inhibitors and car-T cell therapies for the management of haematological malignancies: A systematic review.2023International Journal of Molecular Sciences
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma.2022NICE
Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1–expressing esophageal squamous cell carcinoma: A post hoc analysis of jupiter-06 and meta-analysis.2022Journal of Clinical Oncology
Efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma: A meta-analysis.2022Annals of Surgical Oncology
Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%–49%: A network meta-analysis.2022Thoracic Cancer
Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: A systematic review and network meta-analysis.2022European Urology Open Science
Comprehensive evaluation of anti-PD-1, anti-PD-L1, anti-CTLA-4 and their combined immunotherapy in clinical trials: A systematic review and meta-analysis. 2022Frontiers in Pharmacology
Second‑line treatments for advanced hepatocellular carcinoma: A systematic review and Bayesian network meta‑analysis.2022Clinical and Experimental Medicine
Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: A systematic review and network meta-analysis.2022Journal of Urology
PD-1 inhibitors in esophageal cancer: A systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm.2022Diseases of the Esophagus
Impact of PD1 and PDL1 immunotherapy on nonsmall cell lung cancer outcomes: A systematic review.2022Thorax
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis.2022Critical Reviews in Oncology/ Hematology
Clinical benefts of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: A systematic review and meta-analysis.2022World Journal of Surgical Oncology
Efficacy and safety of immunotherapy for cervical cancer - a systematic review of clinical trials.2022Cancers
How immunotherapy modified the therapeutic scenario of endometrial cancer: A systematic review.2022Frontiers in Oncology
Comparative efficacy of treatments for brain metastases from non-small cell lung cancer without an EGFR-mutation/ALK-rearrangement: A systematic review and network meta-analysis.2022World Neurosurgery
Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials 2021Critical Reviews in Oncology / Hematology
Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: A systematic review and Bayesian network meta-analysis. 2021Journal of Cancer
Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review.2021Head & Neck
Adjuvant therapy of high-risk (stages IIC–IV) malignant melanoma in the post interferon-alpha era: A systematic review and meta-analysis.2021Frontiers in Oncology
Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.2021World Journal of Clinical Oncology
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: A review on the rationale and results of early phase trials.2021Journal of Hematology & Oncology
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.2021Future Oncology
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: A systematic literature review and network meta-analysis.2021BMC Cancer
A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma.2021European Urology
Systematic review and meta‑analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti‑PD‑1 progression: A systematic review and meta‑analysis.2021Clinical and Translational Oncology
The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: A single-arm meta-analysis of noncomparative clinical studies and randomized control trials.2021World Journal of Surgical Oncology
Efficacy and safety of systemic treatments for patients with recurrent/ metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis.2021Pharmacological Research
Immune checkpoint inhibitors for advanced cutaneous squamous cell carcinoma: A systematic review with meta‑analysis.2021Targeted Oncology
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.2021Critical Reviews in Oncology/ Hematology
Comparative efficacy and safety of programmed death-1 pathway inhibitors in advanced gastroesophageal cancers: A systematic review and network meta-analysis of phase III clinical trials.2021Cancers
Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. 2021International Immunopharmacology
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.2021Cancer Treatment Reviews
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: A systematic review and network meta-analysis.2021Therapeutic Advances in Medical Oncology
Prevalence of dermatological toxicities inpatients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.2021PLoS One
Comparison of efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.2021Frontiers in Oncology
The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.2021BMC Cancer
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer.2021Cochrane Database of Systematic Reviews
First-line treatment of metastatic renal cell carcinoma in the immuno-oncology era: Systematic review and network meta-analysis.2020Clinical Genitourinary Cancer
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: A systematic review.2020Therapeutic Advances in Medical Oncology
Systemic therapy for metastatic renal cell carcinoma in the first‑line setting: A systematic review and network meta‑analysis.2020Cancer Immunology, Immunotherapy
Nivolumab plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: A systematic review and network meta-analysis.2020Cancers
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer.2020Cochrane Database of Systematic Reviews
What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.2020BMJ Open
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): A systematic literature review.2020OncoImmunology
Targeted therapy for metastatic renal cell carcinoma.2020Cochrane Database of Systematic Reviews
Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: A systematic review and network meta-analysis.2020Cancers
Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: A systematic review and network meta-analysis.2020JAMA Network
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: Systematic review and meta-analysis.2020European Journal of Clinical Pharmacology
Immune checkpoint inhibitors in advanced acral melanoma: A systematic review.2020Frontiers in Oncology
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis.2020Therapeutic Advances in Medical Oncology
A systematic review and meta-analysis of immune-related adverse events of anti-PD-1 drugs in randomized controlled trials.2020Technology in Cancer Research & Treatment
Systematic review and network meta-analysis of immune checkpoint inhibitors in combination with chemotherapy as a first-line therapy for extensive-stage small cell carcinoma.2020Cancers
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: Systematic review and meta-analysis.2020European Journal of Clinical Pharmacology
Immune checkpoint inhibitors in advanced acral melanoma: A systematic review.2020Frontiers in Oncology
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis.2020Therapeutic Advances in Medical Oncology
Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma.2020Cochrane Database of Systematic Reviews
Systematic review and network meta-analysis of immune checkpoint inhibitors in combination with chemotherapy as a first-line therapy for extensive-stage small cell carcinoma.2020Cancers
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.2019Lung Cancer
Treatment-related adverse events of PD-1 and PD-L1 Inhibitors in clinical trials: A systematic review and meta-analysis.2019JAMA Oncology
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: A network meta-analysis.2019Immunotherapy
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis.2019Journal of Cellular Physiology
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.2019European Journal of Cancer
Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.2019Critical Reviews in Oncology / Hematology
First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: A systematic review and network meta-analysis.2019Clinical Lung Cancer
Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: A systematic review and meta-analysis.2019Frontiers in Immunology
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.2019EBioMedicine
Comparative efficacy of second- and subsequent-line treatments for metastatic NSCLC: A fractional polynomials network meta-analysis of cancer immunotherapies.2019Clinical Lung Cancer
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: Pembrolizumab or pembrolizumab plus chemotherapy.2019Journal for ImmunoTherapy of Cancer
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): A systematic review and network meta-analysis.2019Journal of Thoracic Disease
The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non-small cell lung cancer and melanoma: Network meta-analysis and systematic review.2019Frontiers in Pharmacology
Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis.2019Frontiers in Oncology
Comparison of immune checkpoint inhibitors between older and younger patients with advanced or metastatic lung cancer: A systematic review and meta-analysis.2019BioMed Research International
Comparison of immune checkpoint inhibitors between older and younger patients with advanced or metastatic lung cancer: A systematic review and meta-analysis.2019BioMed Research International
Comparative efficacy of second- and subsequent-line treatments for metastatic NSCLC: A fractional polynomials network meta-analysis of cancer immunotherapies.2019Clinical Lung Cancer
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.2019Journal for ImmunoTherapy of Cancer
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): A systematic review and network meta-analysis.2019Journal of Thoracic Disease
The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non-small cell lung cancer and melanoma: Network meta-analysis and systematic review.2019Frontiers in Pharmacology
Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis.2019Frontiers in Oncology
Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.2019Critical Reviews in Oncology / Hematology

Clinical Practice Guidelines

Document TitleYearSource
Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline.2023Journal of Clinical Oncology
Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology.2023Journal of the National Comprehensive Cancer Network
Systemic therapy for melanoma: ASCO guideline update.2023Journal of Clinical Oncology
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific Region.2023Expert Review of Anticancer Therapy
Follow-up and management of checkpoint inhibitor related toxicities in cancer patients.2022Alberta Health Services
Treatment of metastatic colorectal cancer: ASCO guideline.2022Journal of Clinical Oncology
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.2021Journal for ImmunoTherapy of Cancer
Metastatic colorectal cancer.2021Alberta Health Services
Gastric cancer.2021Alberta Health Services
Renal cell carcinoma.2021Alberta Health Services
Locally advanced/metastatic bladder cancer.2021Alberta Health Services
Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma.2020Annals of Hepatology
Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline.2020Journal of Clinical Oncology
Systemic therapy for melanoma: ASCO guideline.2020Journal of Clinical Oncology
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).2019Clinical and Translational Oncology
Merkel cell carcinoma.2019Alberta Health Services
Lymphoma. 2019Alberta Health Services
Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2019Annals of Oncology
Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology.2019Journal of the National Comprehensive Cancer Network